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Abstract
Background: Anxiety adversely affects quality of life and is common in adults with advanced life-limiting disease.
There are no UK-wide guidelines on the assessment and management of anxiety in this specific population and
there is little evidence regarding drug treatments. This study aimed to explore how palliative care physicians assess
and manage anxiety in their patients, and to identify barriers encountered.
Methods: A cross-sectional survey was undertaken of all physicians working in specialist palliative care in the UK
who were members of the Association for Palliative Medicine. This was conducted in February 2014 using an online
questionnaire.
Results: The response rate was 23% (230/980) and 61% of respondents were consultants. Most did not use tools to
screen for anxiety (87%) and almost all used the clinical interview to diagnose anxiety (99%). Only 8% used
psychiatric criteria. Most physicians reported difficulties managing anxiety (93%). Only 33% thought they had
adequate training in this area. Most had difficulty accessing psychological and/or psychiatric services (71%, 64%
respectively). The majority used a combination of pharmacological and non-pharmacological treatments for anxiety.
The most frequently prescribed first-line medications for patients with a prognosis of days to weeks were
benzodiazepines (93%), usually lorazepam. The use of benzodiazepines over antidepressants was statistically
significant (p < 0.001). For patients with a prognosis of months, antidepressants were most frequently prescribed
first-line (60%), significantly more than benzodiazepines (p < 0.001). However, benzodiazepine use was still common
in this prognostic group with 47% prescribing it first-line, sometimes in combination with an antidepressant.
Conclusion: This is the first national survey on the assessment and management of anxiety in palliative care.
Findings demonstrate the infrequent use of screening tools, variation in prescribing practice, potentially
inappropriate use of benzodiazepines for patients with a prognosis of months, training gaps and poor access to
psychological and psychiatric services in the UK. This highlights the need for formal training, further research into
the pharmacological management of anxiety in this population and evidence-based national guidance to support
clinical decision-making and service development.
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Background
Anxiety is common in adults with advanced life-limiting
disease, adversely affecting quality of life, social relation-
ships and daily functioning at a critical time [1, 2]. It im-
pairs the individual’s ability to cope with their illness,
erodes their trust in physicians, reduces treatment com-
pliance and makes physical symptoms more difficult to
manage [1–3]. Estimates of the prevalence of anxiety
disorder in the palliative care setting range from 6.8 to
13.3% [4], while significant anxiety symptoms are more
common (24–48% [5–7]). However, anxiety is frequently
unrecognised and untreated [1, 8, 9].
Anxiety is a future-oriented mood state associated
with preparation for possible, upcoming negative events
[10]. Pathological anxiety is persistent or recurrent anx-
iety, fear or worry in excess of what is to be expected in
the individual’s situation and causing clinically signifi-
cant distress or impaired functioning [11–13]. Current
psychiatric classifications recognise anxiety as a group of
disorders including generalised anxiety disorder (GAD),
panic disorder, phobias, specified and unspecified anx-
iety disorder [13, 14]. Anxiety symptoms may also be the
prominent feature in stressor-related disorders such as
adjustment disorder [13]. However, it can be difficult to
apply the strict criteria for specific anxiety disorders to
patients with advanced life-limiting disease, although
they experience symptoms of anxiety that cause signifi-
cant distress or functional impairment [12]. A broad def-
inition of anxiety, incorporating all these anxiety states,
is most relevant and practical in the palliative care
clinical setting.
A range of screening tools have been developed to
help physicians identify patients with significant anxiety
who need a more thorough diagnostic interview. The
most extensively validated screening tool in palliative
care populations is the Hospital Anxiety and Depression
Scale (HADS) [15–17]. There are recent guidelines for
cancer patients that have recommended other screening
tools such as the Edmonton Symptom Assessment
System (ESAS), ESAS Revised (ESASr), Generalised
Anxiety Disorder 7-item Scale (GAD-7) and the Distress
Thermometer (DT) [18–20]. Structured diagnostic
interview tools have also been developed, such as the
Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders Fifth Edition
(SCID-5), but the validity of diagnostic tools in the
palliative care setting is questionable [21].
There are no national or international guidelines for
the assessment and management of anxiety in palliative
care patients. Considering the guidance for related popu-
lations, there are Canadian, American and Australian
evidence-based guidelines on the assessment and man-
agement of anxiety and depression in adult cancer pa-
tients [18–20, 22]. These vary in detail and specificity
but all recommend routine screening for anxiety at regu-
lar intervals with validated tools. They advise an indi-
vidually tailored, stepped care model of intervention,
frequently involving a combination of psychological and
pharmacological treatments for moderate to severe anx-
iety symptoms. The Australian guidelines provide the
most specific recommendations regarding medication,
advising selective serotonin reuptake inhibitors (SSRIs)
as first-line pharmacotherapy and advising against
benzodiazepine use due to risk of dependence, tolerance
and other morbidities including confusion, ataxia, falls
in the elderly and rebound anxiety [20]. However, they
advise benzodiazepines can be used in crisis situations,
including palliative care. The National Institute for
Health and Care Excellence (NICE) Guidance on Im-
proving Supportive and Palliative Care for Adults with
Cancer provides UK-based guidance on psychological
distress management in cancer patients [9]. While not
addressing anxiety specifically, it recommends that can-
cer patients experiencing significant psychological dis-
tress be referred to specialist psychological support
services. It proposes a four-level model of psychological
assessment and intervention but does not provide spe-
cific guidance on pharmacological management.
While guidance regarding the assessment and manage-
ment of anxiety specifically in the palliative care popula-
tion is lacking, so too is high-level evidence in this area.
Our Cochrane review, recently updated, and Nübling et
al.’s systematic review both conclude that there is inad-
equate evidence to make any recommendations for
pharmacological treatment of anxiety in the palliative care
population [23–25]. Considering the evidence base in
other populations, research into anxiety treatments within
the cancer population has predominantly been undertaken
in patients with early stage cancer [26]. There is rando-
mised controlled trial (RCT) evidence for benzodiazepine
and antidepressant efficacy in the heterogeneous cancer
population [26, 27]. These RCTs demonstrate short-term
benzodiazepine efficacy (10 days) but no difference com-
pared to placebo at 4 weeks. For the management of GAD
in the general adult population, RCTs demonstrate the ef-
ficacy of antidepressants, benzodiazepines and other med-
ications, but the evidence base for benzodiazepines is
much smaller than for antidepressants and there is an in-
creased risk of discontinuation for lorazepam, due to side
effects, as well as evidence of dependence [28]. Therefore
NICE recommends that benzodiazepines are not pre-
scribed for GAD in the general adult population in the
UK, except for short-term use for 2–4 weeks [28]. How-
ever, given the differing needs, physical fitness and prog-
nosis of palliative care patients compared to the general
population or heterogeneous cancer population, it is diffi-
cult to know how much can be extrapolated from the
existing data and applied to the palliative care population.
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While there is a paucity of high-quality evidence for
pharmacological treatments for anxiety in the palliative
care population, non-pharmacological therapies have been
studied in this specific population. This research suggests
that anxiety improves with cognitive behavioural therapy
(CBT) [29, 30], group support [31], counselling [32] and
some complementary and alternative therapies [33–35].
There is little research directly comparing pharmacological
and non-pharmacological treatment for anxiety in pallia-
tive care [27]. As in the general population, a combination
of pharmacological and psychological therapies may be
more effective than either treatment alone [36, 37], but the
data to support this is limited.
In the absence of a solid evidence base or guidelines
specific to the treatment of anxiety in patients with ad-
vanced life-limiting disease, this study aims to establish,
through a UK-wide survey, how palliative medicine phy-
sicians currently assess and manage anxiety in their pa-
tients. In doing so, it aims to provide vital information
needed to develop national guidelines, improve training
and services and plan relevant research in this area.
Methods
Study design
A cross-sectional survey design using an online platform
to collect quantitative data and some qualitative data.
Survey development
A literature review and previous surveys [38, 39] in-
formed the development of a twenty-eight item web-
based questionnaire. The questionnaire was reviewed by
experts in palliative medicine and psychiatry, and pilot-
tested on seven palliative medicine physicians of varying
grades. Questions were revised accordingly.
For the purpose of the survey, anxiety was defined as
persistent or recurrent anxiety causing clinically signifi-
cant distress or functional impairment. This included
anxiety and stressor-related disorders defined by psychi-
atric criteria, as well as other significant anxiety states.
The questionnaire consisted of 6 sections:
1) Informed consent
2) Demographic details of participants; work setting,
years of palliative care experience and previous
psychological/psychiatric training.
3) Process by which participants diagnosed anxiety in
their patients.
4) Methods participants used to manage anxiety, including
pharmacological and non-pharmacological treatments
in patients with shorter and longer prognoses.
5) Challenges encountered when assessing and
managing anxiety.
6) Access to psychological, psychiatric and other
support services.
Twenty-three questions were multiple choice with op-
tions for additional free text comments. Five were open
questions with free text responses. No personal data was
collected.
Sampling
The sample cohort (n = 980) comprised of all physi-
cians working in adult specialist palliative care in the
UK, who were members of their specialist society (The
Association for Palliative Medicine of Great Britain
and Ireland, APM). They were identified via the APM
database. The cohort included physicians working in
all specialist palliative care settings: inpatient palliative
care unit, hospital consult service, community service,
outpatient service and day unit. All grades of physician
were included: consultants, registrars (training in spe-
cialist palliative care) and non-training career grade
physicians (known as specialty staff grade and associate
specialists, SSAS). Retired APM members and those
working outside the UK were excluded.
Survey administration
In order to ensure anonymity, the APM directly
emailed the survey web link to each physician in
February 2014. To increase response rate, a reminder
email was sent four weeks later and the survey was
open for five weeks. The survey was administered on-
line via SurveyMonkey, an online survey development
company. The survey could only be completed once by
each participant to avoid duplicate surveys.
Data analysis
Only completed surveys were included in the analysis.
To ensure a representative sample of UK specialist pal-
liative medicine physicians, we compared respondents’
specialty grades to those of the total eligible APM mem-
bership and the total UK specialist palliative medicine
workforce, as estimated by the Royal College of
Physicians census [40].
Using Stata Version 12 [41] we described the quanti-
tative responses using percentages. Percentages were
based on the number of respondents answering each
question and were rounded to the nearest whole num-
ber. Pearson Chi², or Fisher’s exact test where appro-
priate, were used to compare groups. Multiple tests
were carried out without adjustments and a p value of
< 0.05 was used as the level of significance. Free text
responses were explored by one researcher (NA) using
thematic content analysis, and themes generated were
verified by a second researcher (BC).
Results
Of 980 surveys emailed, a total of 279 respondents com-
menced the survey, 231 completed it and one of these
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was excluded as they did not meet the eligibility criteria.
Overall, the response rate was 23% (230/980). The ma-
jority of respondents were consultants (61%) and the
most common work setting was the inpatient palliative
care unit (54%). Further respondent characteristics are
reported in Table 1.
Comparison by staff grade with the total APM
sample cohort showed that a slightly higher propor-
tion of respondents were consultant or SSAS grade,
rather than specialty registrar grade. Of the APM’s
membership (n = 980) at the time of the survey, 30%
(141/472) of consultants responded, 33% (48/146) of
SSAS physicians responded and 17% (41/244) of reg-
istrars responded. However, 118 members registered
with the APM were recorded as ‘unknown grade’
but those who completed the survey all documented
a specific grade, and physicians may not have up-
dated their APM records when progressing from one
grade to another, introducing some inaccuracy into
these percentages. Considering grade of respondents
in relation to the estimated total UK specialist pal-
liative care physician workforce [40], there was a
similar over-representation of more senior physicians
and under-representation of trainees. Twenty-eight
percent (141/502) of consultants in the UK
responded and 18% (41/222) of registrars in the UK
responded. Total SSAS workforce data was not avail-
able. It was not possible to compare other variables
due to missing data.
Assessment of anxiety
Anxiety was common, with the majority of physicians
diagnosing it in a quarter or more of their patients
(Table 2). Only a proportion of physicians (28%) were
aware of local or network guidelines. Most did not use
screening tools for anxiety (87%) and used the clinical
interview to diagnose anxiety (99%). A small minority
used psychiatric criteria (8%) or a diagnostic tool (12%)
in addition to the clinical interview for diagnosis. Where
a tool was used, the HADS was the most popular for
screening and diagnosis (52% and 81%, respectively).
Management of anxiety
Physicians were asked about their management strat-
egies for two different groups of patients, those with a
likely prognosis of days to weeks (d-w) and those with a
likely prognosis of months (m).
All but one respondent reported that they treated anx-
iety when diagnosed. A small proportion recommended
only non-pharmacological treatments first-line, usually
for patients with a longer prognosis (4% d-w, 14% m).
Also, a few respondents recommended only pharmaco-
logical treatments first-line, usually for patients with a
shorter prognosis (8% d-w, 2% m). However, the major-
ity used a combination of pharmacological and non-
Table 1 Characteristics of respondents
Characteristics n (%)
(n = 230)









Main work setting Inpatient palliative
care unit
124 (54)
Hospital consult service 48 (21)
Community 27 (12)
Outpatient/day unit 6 (3)
Equal split across settings 25 (11)
Geographical location England 188 (82)
Scotland 20 (9)
Wales 15 (7)
Northern Ireland 5 (2)
Abbreviations: SSAS specialty staff grade and associate specialists
Table 2 Assessment of Anxiety
n (%)
(n = 230)




Have local or network guideline 65 (28)
Use screening tool routinely 29 (13)
Screening tool used (n = 29) HADS 15 (52)
DT 7 (24)
ESAS 2 (7)
Other tool 5 (17)
Diagnose using (tick all that apply) Clinical interview 227 (99)
DSM-5 or ICD-10 18 (8)
Diagnostic tool 27 (12)
Diagnostic tool used (n = 27) HADS 22 (81)
GAD-7 1 (4)
BEDS 2 (7)
Other tool 2 (7)
Routinely assess suicide risk
when anxiety diagnosed
79 (34)
Abbreviations: DSM-5 Diagnostic and Statistical Manual of Mental Disorders
Fifth Edition, DT Distress Thermometer, ESAS Edmonton Symptom Assessment
System, GAD-7 Generalised Anxiety Disorder 7-item Scale, HADS Hospital
Anxiety and Depression Scale, ICD-10 International Statistical Classification of
Diseases Tenth Revision, BEDS Brief Edinburgh Depression Scale
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pharmacological treatments first-line for both groups
(88% d-w, 84% m). The majority of physicians (56%)
adopted the same management approach for patients
with specific anxiety disorders defined by psychiatric cri-
teria as they did for other patients with anxiety. Where
management changed, this was most often in seeking
psychiatric input.
1. Non-pharmacological Management
When non-pharmacological management was offered,
this usually involved a combination of multiple non-
pharmacological therapies. Supportive care from the pal-
liative care team, chaplaincy input and complementary
therapies were recommended for most patients in both
prognostic groups (Fig. 1). Psychological therapies and
psychiatric input were more frequently recommended
for those with a longer prognosis. Of these, counselling
was most commonly offered (40% d-w, 72% m), followed
by CBT (10% d-w, 43% m), psychiatry input (8% d-w,
24% m) and psychotherapy (5% d-w, 23% m).
2. Pharmacological Management
First and second-line medications for each group are re-
ported in Table 3.
Prognosis days to weeks
Benzodiazepines were the most common first-line anxio-
lytic medication for patients with a prognosis of days to
weeks (93%). Use of these in preference to antidepres-
sants was statistically significant (p < 0.001).
Where a single benzodiazepine was specified, this was
usually lorazepam (86%), followed by diazepam (7%) and
midazolam (5%). The most common second-line drug
choice was an alternative benzodiazepine (70%), most
often midazolam.
Where medication dosing regimes were specified, lor-
azepam was usually prescribed ‘as needed’/pro re nata
(PRN) rather than regularly (84% PRN, 16% regularly)
and given via the sublingual route (72%). The most com-
mon starting dose was 0.5-1 mg (53%) but PRN doses
ranged from 0.5 mg to 2 mg with a maximum frequency
of twice daily to hourly. Midazolam doses were more
variable, with PRN starting doses ranging from 1.25 mg
to 10 mg and continuous infusion starting doses ranging
from 2.5 mg to 15 mg over 24 h. Diazepam starting
doses ranged from 2 mg to 10 mg, with frequencies of
once to four times daily.
Prognosis months
The majority of respondents (63%) used a different drug
regime for those whose prognosis was months. Antide-
pressants were the most common first-line anxiolytic
medication (60%). Use of these in preference to benzodi-
azepines was statistically significant (p < 0.001) but use
of benzodiazepines was still common (47%, some in
combination with antidepressants). Of the antidepres-
sants, citalopram was most frequently prescribed (54%),
followed by mirtazapine (38%) and sertraline (6%). The
most common second-line medication choice was a
benzodiazepine (46%), usually lorazepam (59%).
For both prognostic groups other drugs used first-line
included haloperidol, levomepromazine, promazine,
pregabalin, oxazepam, duloxetine and nortriptyline.
There was even greater variation in second-line drugs.
Fig. 1 Non-pharmacological management of anxiety
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Challenges encountered and access to support services
The majority of physicians reported difficulties assessing
anxiety (71%; Fig. 2), particularly differentiating a patho-
logical state from a ‘normal’ reaction to diagnosis or
impending death. Almost all physicians found anxiety dif-
ficult to manage (93%). The most commonly reported
challenges were accessing timely non-pharmacological
therapies, managing medication side-effects and refractory
anxiety. Thirty percent thought they did not have ad-
equate training in the assessment and management of
anxiety, and a further 37% were unsure whether they did.
Those with more years of experience in palliative care or a
more senior grade were more likely to feel adequately
trained (p = 0.04, p = 0.02). Previous psychiatric or psycho-
logical training and a more senior grade were associated
with less difficulty assessing anxiety (p = 0.04, p = 0.001).
However, as almost all respondents reported difficulties
managing anxiety, there was only a trend towards reduced
difficulties with previous training, years of experience and
more senior grade (p = 0.57, p = 0.16, p = 0.07).
Most physicians had direct access to chaplaincy, com-
plementary therapies and counselling (96, 90, 73% re-
spectively). However, direct access to psychology and
psychiatry was less common (45, 44%) and the majority
of physicians reported difficulties accessing these ser-
vices (71, 64%). In the case of psychology and CBT ser-
vices, difficulties were most often due to inappropriately
long waiting times for appointments for patients with a
short prognosis, no local service provision or staff short-
ages. The main challenges regarding access to psychi-
atric services were the services’ reluctance to see
palliative care patients, particularly in the hospice set-
ting, inappropriately long waiting times to be seen and
the lack of formal or direct referral systems.
Many respondents reported initiatives within their
own services that had improved their clinical manage-
ment of anxiety, or suggested changes they felt would
address current challenges. These included additional
training for themselves (formal teaching, CBT train-
ing, psychiatric placements), having in-house staff
CBT trained, employing a psychologist or psychiatrist
part-time to review patients and upskill the team, de-
veloping relationships and service level agreements
with local psychological and psychiatric services, and
the creation of national guidelines.
Discussion
This survey demonstrates that the majority of palliative
care physicians find anxiety difficult to manage, although
it is so common in their patient population. The findings
highlight several key issues, which may be amenable to
improvement, including the infrequent use of validated
screening tools, wide variation in prescribing practice,
Table 3 Pharmacological Management of Anxiety




n (%) n (%)
1st Line (n = 216) (n = 211)
Benzodiazepine (BZ) 200 (93) 99 (47)
Alone 188 (87) 78 (37)
Combined
(with another drug class)
12 (6) 21 (10)
Where BZ specified: (n = 147) (n = 73)
Lorazepam 127 (86) 60 (8)
Diazepam 11 (7) 13 (18)
Midazolam 8 (5) 0 (0)
Antidepressant (AD) 21 (10) 127 (60)
Alone 12 (6) 107 (51)
Combined (with BZ) 9 (4) 20 (9)
Where AD specified: (n = 17) (n = 93)
Mirtazapine 12 (71) 35 (38)
Citalopram 3 (18) 50 (54)
Sertraline 2 (12) 6 (6)
Other Medications
Haloperidol 4 (2) 2 (1)
Levomepromazine 2 (1) 0 (0)
Pregabalin 0 (0) 4 (2)
2nd Line (n = 142) (n = 124)
Benzodiazepine 99 (70) 57 (46)
Where BZ specified: (n = 96) (n = 49)
Midazolam 46 (48) 4 (8)
Diazepam 31 (32) 16 (33)
Lorazepam 18 (19) 29 (59)
Antidepressant 26 (18) 55 (44)
Where AD specified: (n = 18) (n = 41)
Mirtazapine 9 (50) 22 (54)
Amitriptyline 4 (22) 1 (2)
Citalopram 3 (17) 11 (27)
Sertraline 1 (6) 5 (12)
Other Medications
Levomepromazine 9 (6) 3 (2)
Pregabalin 2 (1) 8 (6)
Morphine 2 (1) 3 (2)
Unspecified antipsychotic 3 (2) 0 (0)
Medications used by n = 1 or less respondents in both prognostic groups not
included in table
n numbers: variation as non-compulsory free text answers so some
respondents answered only part of question, some specified drug and others
only gave drug class
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potentially inappropriate use of benzodiazepines, gaps in
training and poor access to mental health services.
Our results show that most palliative care physicians
in the UK are not using standardised, validated tools to
assess anxiety. Although there is a paucity of data on the
impact of screening for anxiety in the palliative care
population, there is RCT evidence demonstrating the
benefits of screening in the cancer population, if appro-
priate follow-up can be provided [42]. Recent evidence-
based guidelines for cancer patients all recommend
routine screening for anxiety using validated tools,
followed by clinical interview when screening positive
[18–20]. While the palliative care population differs
from cancer population, whose disease is at various
stages, this evidence and international consensus for
the cancer population raises the possibility that
screening tools should be used in the palliative care
population too, particularly as anxiety is under-
diagnosed [1, 8, 9]. Meanwhile, evidence for the valid-
ity of diagnostic (case-finding) tools is lacking in both
palliative care and cancer populations [21, 43].
Despite this, our study shows that some palliative
care physicians in the UK are using tools such as the
HADS for diagnosis. These findings confirm the need for
further study of assessment tools for anxiety in the pallia-
tive care population and for specific guidelines to support
palliative medicine physicians in the UK.
Our study demonstrates widespread use of benzodiaz-
epines for anxiety management, even for palliative care
patients with a prognosis of months. Although there are
no national guidelines specific to this population, the
2014 NICE Quality Standard for Anxiety Disorders and
American and Australian guidelines for cancer patients
all advise against prescribing benzodiazepines for anxiety
except in short-term crisis situations, due to significant
adverse effects and the development of tolerance and de-
pendence [19, 20, 44]. While the evidence base for the
pharmacological management of anxiety in the palliative
care population is lacking, data from cancer populations
demonstrates the short-term (days to weeks) rather than
longer-term benefit of benzodiazepines [27]. In the gen-
eral adult population the evidence base for benzodiaze-
pines is smaller than that for anxiolytic antidepressants
and the risk of side effects greater [28]. In view of this
significant body of research and the overlap between the
heterogeneous cancer population and palliative care pa-
tients with a prognosis of months, it is possible that the
common use of benzodiazepines in this latter group, as
identified in our study, may not be the safest or most ef-
fective treatment approach. Our results also demonstrate
substantial variation in drug choice and dosing, a further
indication that some patients may not be receiving the
most appropriate treatment. These issues highlight a
major gap in the evidence base for anxiety management
in palliative care and the need for UK guidance on pre-
scribing for these patients.
Our results show that despite anxiety being a common
problem among palliative care patients, almost all pallia-
tive care physicians, even the most experienced, have diffi-
culty managing anxiety. As the majority of physicians feel
they do not have adequate training in this area, or are un-
sure whether they do, our findings suggest gaps in training
may be contributing to their difficulties and potentially
impacting on patient care. Survey respondents identified
that further training, closer links with experts and relevant
guidelines would be beneficial, which is consistent with
Fig. 2 Difficulties encountered by respondents
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other studies of physician-perceived barriers to psycho-
social care at the end of life [45, 46].
However, the most common difficulty respondents re-
ported with regards to anxiety management was lack of
access to timely non-pharmacological therapies, particu-
larly from psychology and psychiatry services. This is
contrary to NICE guidance which recommends that can-
cer patients (irrespective of disease stage) experiencing
significant psychological distress should be offered
prompt referral to specialist psychological support ser-
vices [9]. It also recommends that all palliative care
teams should have access to these services, close work-
ing relationships with mental health teams and adequate
training in providing general psychological support.
Price et al.’s survey of the availability of psychological
services in hospices in the UK and Ireland in 2005 found
that there was inadequate access to psychologists and
psychiatrists [47]. Our survey, conducted 9 years later,
demonstrates some improvement in service provision.
Physicians working in hospices now have dramatically
improved access to counselling for their patients (76% in
2014 versus 38% in 2005). However, despite the NICE
guidance, there has been only a marginal improvement
in access to psychologists and psychiatrists in hospices
over this period (46% versus 41% for psychology, 37%
versus 30% for psychiatry).
The issues identified in our survey are not unique to the
UK or the hospice setting. Patterson et al.’s 2014 survey of
American hospital-based palliative care consult services
demonstrated that most respondents (71%) would like
psychiatry to be more involved with the palliative care ser-
vice than they currently are, and the barriers identified
were similar to our study [48]. However, the American
survey found that 72% of consult services had some in-
volvement with a psychiatrist, suggesting better engage-
ment between psychiatry and palliative care than in the
UK, where only 56% of the hospital-based palliative care
physicians in our survey had direct access to psychiatry. In
support of improved psychiatric involvement, Patterson’s
survey demonstrated that palliative care teams with an
identified psychiatrist were more likely to report that their
patients’ mental health needs were being met.
Limitations
The major limitation of this study was the low response
rate, despite reminder emails to all physicians. This is un-
fortunately common for web-based surveys distributed by
email [49]. It is challenging to access these professionals at
a national level as they work in a range of different organi-
sations and settings. However, as the first survey on this
topic, a national web-based survey method was chosen to
give the broadest reflection of UK-wide practice and act as
a starting point for more detailed, targeted study. We are
aware that this low response rate may impact on the
representativeness of the sample and increases the risk of
response bias. The results are more likely to reflect the
views of physicians with an interest in anxiety and it is
therefore possible that the knowledge gaps and training
needs are even greater than those identified in the study.
Representativeness of the sample is further affected by the
disproportionately higher response rate from consultants
and SSAS physicians than registrars, more junior physi-
cians. This may have impacted on our estimate of the
knowledge gaps and training needs of the UK specialist
palliative care physician workforce. However, accurate
analysis of the representativeness of the sample in this
study is limited by missing UK workforce and APM
membership data.
There were several other limitations. Due to the survey
format, this study relied on respondents’ subjective re-
ports of their practice, rather than more objective and
prospective assessments. The use of some survey ques-
tions with free text answers meant those responses were
open to interpretation when categorising and analysing
the data. Moreover, some optional, clarifying comments
were made by only a small proportion of respondents so
it is difficult to draw valid conclusions from those quali-
tative responses. Also, as part of the statistical analysis
multiple tests were carried out without adjustments as it
was an exploratory analysis. Finally, the survey was con-
ducted in 2014 and it is possible that there have been
changes in practice since, particularly as new or updated
guidelines (for cancer patients and the general popula-
tion) were produced shortly before and after the data
collection [18–20, 24].
Conclusion
To our knowledge this is the first national survey explor-
ing how palliative medicine physicians assess and man-
age anxiety in their patients. It highlights the infrequent
use of screening tools, substantial variation in prescrib-
ing practice, potentially inappropriate use of benzodiaze-
pines in patients with a prognosis of months, training
gaps and poor access to psychological and psychiatric
services in the UK. This suggests that palliative medicine
physicians should receive formal training in the manage-
ment of anxiety and develop local referral networks with
mental health services. The findings also highlight the
urgent need for further research into the pharmaco-
logical management of anxiety in the palliative care
population. The development of a UK-wide guideline is
an essential next step in supporting clinical decision-
making, service development and ultimately improving
patient care.
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